Oxford Biomedica announces new board member amid shifts in leadership.
- Colin Bond, an experienced pharmaceutical executive, joins the Oxford Biomedica board.
- Leone Patterson steps down from the board to focus on her new role at Zymeworks.
- Oxford Biomedica faces significant financial challenges with substantial losses reported.
- The company is known for its leadership in gene and cell therapy innovation.
Oxford Biomedica, a prominent player in the gene and cell therapy sector, has made a strategic addition to its leadership team with the appointment of Colin Bond to its board. Bond, an executive with vast experience in the pharmaceutical industry, is set to join the board in January 2025. His career trajectory includes significant roles at prestigious firms such as Procter & Gamble, Arthur Andersen, and PwC, culminating in his recent position as Chief Financial Officer at Sandoz, a company listed on the Zürich Stock Exchange. Bond has also served in executive roles at Vifor Pharma and Evotec.
In parallel with Bond’s appointment, the company has announced the resignation of Leone Patterson from her role as a non-executive board member. Patterson is leaving to dedicate her efforts to her newly acquired responsibilities as Chief Financial Officer and Chief Business Officer at Zymeworks. Oxford Biomedica, through its chair Roch Doliveux, expressed gratitude for Patterson’s insightful contributions and wished her well in her future endeavours.
Founded in 1995, Oxford Biomedica has established itself as a leader in the development and manufacturing of gene and cell therapies aimed at treating and preventing diseases. Despite its well-regarded position in the industry, the company reported an operating loss of £184.2 million for the year ending December 2023, a severe increase over the £30.2 million loss recorded in 2022. This financial setback was compounded by a revenue decline exceeding a third, bringing in £89.5 million for the same period.
The company’s share price was recorded at 410.43p as of 18 November, reflecting ongoing market evaluations and investor sentiments. The recent appointment of Colin Bond is seen as a positive step towards navigating these financial challenges, bringing his financial expertise and leadership to bolster Oxford Biomedica’s future growth. Bond himself has expressed enthusiasm for the role, recognising the company’s innovative capabilities and strong partnerships as compelling prospects. “Oxford Biomedica’s position as a leader in cell and gene therapy manufacturing…presents a compelling opportunity that I have recently watched with interest,” Bond commented.
Oxford Biomedica is poised for potential growth with recent leadership changes as it navigates financial hurdles.
